- Research Article
- 10.1016/j.jseint.2025.101540
Tuberosity Displacement in Reverse Shoulder Arthroplasty: Impact in Tuberosity Healing, Resorption and Range of Motion
- Mar 01, 2026
- JSES International
- A.r Senra + 12 more +12
Publications from 2021 to 2026
Showing 10 of 123 papers
Tuberosity Displacement in Reverse Shoulder Arthroplasty: Impact in Tuberosity Healing, Resorption and Range of Motion
Long-Term Outcome of Isolated Duodenal Transit Bipartition as Initial Metabolic Surgery: A 19-Year Follow-Up Case Report
Patient: Female, 40-year-oldFinal Diagnosis: ObesitySymptoms: ObesityClinical Procedure: —Specialty: SurgeryObjective: Unusual clinical courseBackgroundMetabolic and bariatric surgeries (MBS) are effective treatments for obesity and related comorbidities, such as diabetes and hypertension. In patients with morbid obesity and challenges like hepatomegaly, conventional procedures may increase risks. Staged MBS was developed to address these issues, enhancing safety. This report highlights the successful use of isolated intestinal transit bipartition with duodeno-ileal anastomosis, preserving the duodenum, as the first stage of the duodenal switch.Case ReportA 40-year-old woman with a BMI of 40.2 kg/m2 was booked for MBS. Severe hepatomegaly impaired safe access to the esophagogastric junction, leading to the performance of only the intestinal stage of the duodenal switch. A duodeno-ileal anastomosis was created 250 cm from the ileocecal valve, preserving the stomach and partial duodenal function. Without the gastric stage, the patient achieved 50 kg of weight loss (equivalent to 78.7% excess weight loss) over 19 years, without requiring additional surgery. Minor complications included occasional diarrhea, meteorism, and difficulties with vitamin supplementation, all managed effectively through dietary adjustments and nutritional guidance. A benefit was increased satiety.ConclusionsIsolated intestinal transit bipartition with duodeno-ileal anastomosis is an approach that may be used in exceptional cases, such as with this patient. Despite the favorable long-term follow-up results, further studies are necessary to better understand this approach. This method demonstrated sustained weight loss and long-term metabolic control, potentially representing a promising initial treatment option for patients with lower BMIs, including those with type 2 diabetes.
Read moreA narrative review and expert consensus on barriers, facilitators, and research gaps to healthy and positive ageing - Position of the Multidisciplinary International Positive Ageing Group (MIPAG).
Recent developments in healthcare and scientific research have shifted the perception of ageing from a period of decline to recognising its potential for sustained functional ability, well-being, and societal contributions. In light of this perspective, a multidisciplinary panel of experts from five European countries conducted a narrative review of the literature. It convened for a one-day consensus meeting to identify key barriers, facilitators, and research priorities related to healthy ageing. Thus, this paper aims to (1) define the concept of positive ageing, (2) discuss barriers and facilitators to healthy ageing, (3) examine the role of healthcare professionals in maintaining and improving intrinsic capacity, and (4) propose a research agenda to address gaps in healthy ageing. The panel identified 70 barriers and 64 facilitators, structured within the WHO's ICOPE framework, related to intrinsic capacity. Twenty-six interventions across five domains-locomotor, sensory, psychological, cognitive capacities, and vitality- were proposed, aimed at both frail and robust individuals, focusing on social integration, psychological well-being, physiological resilience, deficit management, and disorder prevention. The panel also outlined a research agenda emphasising AI-driven ageing support, improved communication strategies, early frailty detection, and the development of locally adapted guidelines and infrastructure for healthy and positive ageing. This framework emphasizes the importance of early-life interventions and advocates for a preventive, holistic, and multidisciplinary approach to aging. In conclusion, the MIPAG's fosters a proactive mindset and early interventions throughout life to prevent the decline and optimise intrinsic capacity.
Read moreGastric Bipartition with Functional Duodenum Exclusion (GBp-FDE) as a Possible Surgical Conversion of Sleeve Gastrectomy in Patients with De Novo GERD and Obesity Recidivism: Preliminary Results of a Case Series.
BACKGROUND Sleeve gastrectomy (SG) is widely used in obesity treatment, although it is associated with new onset of gastroesophageal reflux disease (de novo GERD) and weight regain. Roux-en-Y gastric bypass (RYGB) is the standard revisional procedure for GERD, though it offers limited additional weight loss. Ileal-based procedures have demonstrated superior outcomes regarding weight loss but have uncertain results in GERD. This study presents preliminary findings on gastric bipartition with functional duodenal exclusion (GBp-FDE) as a revisional approach following SG in this scenario. CASE REPORT A retrospective data analysis was conducted on 10 patients who underwent GBp-FDE due to de novo GERD and obesity recurrence after SG (mean BMI: 37.2±3.2 kg/m²). Nine patients presented with hiatal hernia and 8 with sleeve dilation. GERD was assessed pre- and postoperatively using a validated questionnaire, endoscopy, and contrast radiology. The surgical technique involved a pre-pyloric antroileostomy in Roux-en-Y configuration using a 40% proportion biliopancreatic limb. One-year postoperative findings included pyloric spasm (endoscopy), very preferential contrast flow to the ileum (radiology), and endoscopic access preservation to the duodenum. GERD symptoms resolved in 90% (P=0.0059) and esophagitis healed in 80% (P=0.008), likely due to gastric decompression. Mean percent total weight loss and percent excess weight loss were 35.2±6.6 and 108.0±11.14, respectively. CONCLUSIONS GBp-FDE seems to be a promising surgery for managing de novo GERD and obesity recurrence after SG, through SG pouch decompression and ileal stimuli, promoted by the antroileostomy. Further controlled studies with extended follow-up are necessary to validate these findings.
Read moreSociodemographic factors and biologic therapy exposure impacting health-related quality of life in psoriatic arthritis - findings from a nationwide registry Reuma.pt.
Psoriatic arthritis (PsA) is a very heterogeneous disease with significant impact on health-related quality-of-life (HRQoL). Our objective was to assess and identify predictors of HRQoL in a 3-year follow-up period among PsA patients. Patients with PsA included in the Rheumatic Diseases Portuguese Register (Reuma.pt), with HRQoL data measured by the EuroQoL five Dimensions (EQ-5D) with at least two evaluations throughout a 3-year period, were analysed. Statistics included t-tests, logit and linear mixed models and univariable and multivariable linear regression. PsA patients' (n = 342) mean age 51.0 (12.2) years, 48.5% being female, mean disease duration 11.8 (9.3) years with a follow-up period of 3-years had a mean EQ-5D of 0.53 (0.28), 0.59 (0.29), and 0.58 (0.28) at baseline, 1-year and 3-year evaluations, respectively. During the follow-up period, EQ-5D score and EQ VAS, significantly improved at both time-point assessments, compared to baseline. Poorer HRQoL was significantly associated with older age (β=-0.004; p-value = 0.008), female sex (β=-0.092; p-value = 0.01), non-employment (β=-0.112; p-value = 0.018), higher disease activity (β=-0.005; p-value < 0.001), prior exposure of three or more biologics at baseline and switching of biologic therapy during the study follow-up [(β=-0.182; p-value = 0.04); (β=-0.150; p-value = 0.002), respectively]. Our study provides important insights into the long-term predictors of HRQoL in PsA patients, highlighting the influence of sociodemographic factors, disease activity and therapeutic approach (prior use and switch/cycle of biologic therapies) on HRQoL.
Read moreTransoral outlet reduction (TORe) for treatment of weight regain after biliopancreatic diversion in a patient with Prader-Willi syndrome and super-super obesity: report of the first case.
This is the first report to present a novel application of TORe for anatomical revision in a patient with Prader-Willi syndrome and super-super obesity, following substantial weight regain after Scopinaro surgery performed 9years prior. The procedure involved APC-induced mucosal ablation and endoscopic full-thickness suturing. Postoperatively, the patient achieved 34% excess weight loss and 25.4% total body weight loss at 3months, sustained at 41% EWL and 31% TBWL at 12months. Improvements included resolution of obstructive sleep apnea, glycemic optimization, and improvement in functional capacity.
Read moreSuccinate dehydrogenase B (SDHB) overexpression with enzymatic dysfunction defines a distinct subtype of undifferentiated pleomorphic sarcoma
Abstract Undifferentiated pleomorphic sarcoma (UPS) remains one of the most clinically aggressive and poorly characterized soft tissue sarcoma (STS) subtypes. To uncover distinctive molecular traits for UPS, a multi-omics analysis of UPS compared to leiomyosarcoma (LMS), and liposarcoma (LPS) was performed. Transcriptomic profiling revealed that UPS exhibits overexpression of genes encoding succinate dehydrogenase (SDH) subunits, particularly SDHB, SDHC, and SDHD, distinguishing it from LMS and dedifferentiated LPS (DDLPS). This finding was validated using the TCGA-SARC dataset. High SDHB expression in UPS was significantly associated with shorter overall survival (OS) and shorter OS from the date of first metastasis. Immunohistochemistry validated elevated SDHB protein levels in UPS and LMS relative to DDLPS. Despite overexpression of SDH subunits, metabolomic profiling demonstrated a significantly higher succinate-to-fumarate ratio in UPS, suggesting functional impairment of SDH enzymatic activity potentially due to post-translational modifications, altered assembly of SDH subunits, or imbalanced tricarboxylic acid (TCA) flux. This paradoxical phenotype of SDH overexpression with enzymatic dysfunction defines a unique molecular and metabolic subtype of UPS with prognostic significance. Recognition of this distinct SDH- associated molecular and metabolic phenotype provides insight into UPS pathogenesis, identifies a potential novel prognostic biomarker, and suggests a new avenue for metabolic-targeted therapy.
Read moreValue-Based Geriatric Care: Good News from Portugal.
N/A
Five years of the Early-Career Geriatricians Initiative (ECGI): reflecting on the past, shaping the present, and envisioning the future
Despite rising global demand, geriatrics is often overlooked by young physicians due to its perceived complexity and limited career development. Launched by the European Geriatric Medicine Society, the Early Career Geriatricians Initiative (ECGI) aims to counter this perception with its rich educational, research, and leadership opportunities. This article provides a narrative overview of the ECGI, highlighting its establishment, key milestones, and impact within the EuGMS, while also outlining its structure, major achievements, and future directions. The ECGI set strategic objectives to integrate early-career geriatricians into EuGMS activities. Key actions included the establishment of working groups, the introduction of a Rotation Program for international observerships, and the organization of dedicated congress events such as the Comprehensive Geriatric Assessment (CGA) Quiz and the Stefania Maggi Award Symposium. ECGI members were also given opportunities to represent the initiative in international conferences. Since gaining official recognition as a Special Interest Group of EuGMS in 2024, the initiative has been steadily evolving, aiming to establish a more structured, sustainable framework that enhances its long-term impact and effectiveness within the geriatric community. As it marks its fifth anniversary, the ECGI remains committed to empowering the next generation of geriatricians with helping their professional growth and engagement. The early-career geriatricians are encouraged to join ECGI and contribute to shaping the future of geriatric medicine.
Read moreCCL2 expression predicts clinical outcomes and regulates E-cadherin and angiogenesis in pituitary tumours.
The crosstalk between tumour cells and microenvironment components in pituitary neuroendocrine tumours (PitNETs), including chemokines, may impact tumour behaviour and clinical outcomes. CCL2 was previously identified as a key chemokine in PitNETs, but its role remains unknown. We aimed to study the role of CCL2 in defining the phenotype and clinical outcomes of PitNETs and in regulating macrophage chemotaxis, epithelial-to-mesenchymal transition (EMT) and angiogenesis. We studied CCL2 and E-cadherin expression, macrophages (CD68 and CD163) and vessels (CD31) in samples from 86 PitNET patients. Higher CCL2 mRNA expression was found in patients who required multimodal and multiple treatments and had active disease at the last follow-up. Higher CCL2 immunoreactivity was observed in patients with larger PitNETs. Among somatotroph tumours, CCL2 mRNA expression correlated with serum IGF-1 at the last follow-up. CCL2 mRNA expression levels correlated negatively with CDH1 expression and with E-cadherin complete membranous staining. In vitro, CCL2 downregulated E-cadherin expression in GH3 cells but did not affect cell morphology or migration. CCL2 expression correlated with the number of vessels, vessel perimeter and vessel area in PitNETs but not with PitNET-infiltrating macrophages. Our data suggest that CCL2 may lead to (or is at least a predictive marker of) poorer clinical outcomes and more difficult-to-treat PitNETs, potentially through its regulatory effects on different tumour-related mechanisms beyond immune cell chemotaxis, including in the activation of the EMT pathway and modulation of angiogenesis in PitNETs. Further studies are needed to corroborate our findings and to validate CCL2 as a potential predictive marker and therapeutic target in PitNETs.
Read more